📊 ZVSA Key Takeaways
Is ZyVersa Therapeutics, Inc. (ZVSA) a Good Investment?
ZyVersa is in acute financial distress with negative stockholders equity of -$12.4M, a critically low current ratio of 0.03x, and only $101.8K in cash against $12.7M in liabilities. With $5.1M quarterly cash burn and near-total revenue collapse (-90% YoY), the company faces imminent solvency crisis and likely bankruptcy or catastrophic equity dilution within months.
ZyVersa Therapeutics, Inc. Key Strengths (ZVSA)
- Pharmaceutical sector with potential patent/pipeline assets
- Recent financial reporting (data as of 2025-12-31) provides visibility
- Company remains operational despite distress
ZVSA Stock Risks: ZyVersa Therapeutics, Inc. Investment Risks
- Negative stockholders equity indicates technical insolvency
- Critical liquidity crisis: 0.03x current ratio with inadequate cash for obligations
- Quarterly cash burn of $5.1M far exceeds remaining $101.8K cash reserves
- Revenue collapsed 90% YoY with no viable path to profitability
- High bankruptcy risk; dilutive financing or restructuring likely imminent
- Biotech development execution risk with no visible clinical progress
Key Metrics to Watch
- Cash balance and runway (critical survival metric)
- Any financing announcements or capital raises
- Quarterly cash burn rate and operating expenses
- Revenue stabilization or return to growth
- Clinical trial results and pipeline advancement
ZyVersa Therapeutics, Inc. (ZVSA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 996.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
ZVSA Profit Margin, ROE & Profitability Analysis
ZVSA vs Healthcare Sector: How ZyVersa Therapeutics, Inc. Compares
How ZyVersa Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ZyVersa Therapeutics, Inc. Stock Overvalued? ZVSA Valuation Analysis 2026
Based on fundamental analysis, ZyVersa Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ZyVersa Therapeutics, Inc. Balance Sheet: ZVSA Debt, Cash & Liquidity
ZVSA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ZyVersa Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-8.48 indicates the company is currently unprofitable.
ZVSA Revenue Growth, EPS Growth & YoY Performance
ZyVersa Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ZVSA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ZyVersa Therapeutics, Inc. (CIK: 0001859007)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZVSA
What is the AI rating for ZVSA?
ZyVersa Therapeutics, Inc. (ZVSA) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZVSA's key strengths?
Claude: Pharmaceutical sector with potential patent/pipeline assets. Recent financial reporting (data as of 2025-12-31) provides visibility.
What are the risks of investing in ZVSA?
Claude: Negative stockholders equity indicates technical insolvency. Critical liquidity crisis: 0.03x current ratio with inadequate cash for obligations.
What is ZVSA's revenue and growth?
ZyVersa Therapeutics, Inc. reported revenue of $-513.2K.
Does ZVSA pay dividends?
ZyVersa Therapeutics, Inc. does not currently pay dividends.
Where can I find ZVSA SEC filings?
Official SEC filings for ZyVersa Therapeutics, Inc. (CIK: 0001859007) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZVSA's EPS?
ZyVersa Therapeutics, Inc. has a diluted EPS of $-4.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ZVSA's fundamental grade?
Based on our AI fundamental analysis in June 2026, ZyVersa Therapeutics, Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ZVSA stock overvalued or undervalued?
Valuation metrics for ZVSA: ROE of N/A (sector avg: 15%), net margin of 4,862.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ZVSA's AI grade for 2026?
Our dual AI analysis gives ZyVersa Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ZVSA's free cash flow?
ZyVersa Therapeutics, Inc.'s operating cash flow is $-5.1M, with capital expenditures of N/A. FCF margin is 996.5%.
How does ZVSA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4,862.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).